The SURMOUNT-3 trial article, linked to elsewhere in this document, has excellent visual aids showing comparisons between 5mg, 10mg & 15mg on many health markers, including cholesterol lowering results.
“Reduction in triglycerides and cholesterol: After 52 weeks, the highest dose, Mounjaro reduced total cholesterol by about 5.6%, triglycerides by 22.5%, LDL cholesterol by 7.9%, VLDL by 21.8%, and increased HDL by 10.8%.”
https://beyondtype2.org/diabetes-medication-tirzepatide-mounjaro/
The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
Diabetes, Obesity Metabolism, December 2020